- Home
- KEN vs TERN Comparison
KEN vs TERN Comparison
Compare KEN & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KEN | TERN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.8B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KEN | TERN |
|---|---|---|
| Price | $89.57 | $52.97 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $45.22 |
| AVG Volume (30 Days) | 26.7K | ★ 4.2M |
| Earning Date | 05-27-2026 | 05-14-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | ★ 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.99 | $2.82 |
| 52 Week High | $95.93 | $53.19 |
Technical Indicators
Market Signals| Indicator | KEN | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 74.51 |
| Support Level | $78.28 | $52.42 |
| Resistance Level | $89.89 | $53.19 |
| Average True Range (ATR) | 2.55 | 0.07 |
| MACD | 0.30 | -0.31 |
| Stochastic Oscillator | 60.34 | 97.30 |
Price Performance
Historical ComparisonAbout KEN Kenon Holdings Ltd.
Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.